Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp

Structure Therapeutics (NASDAQ:GPCR) had its price objective decreased by Citizens Jmp from $120.00 to $113.00 in a research report sent to investors on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

GPCR has been the topic of a number of other research reports. Guggenheim raised their price target on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Morgan Stanley raised their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, HC Wainwright lifted their price objective on Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $105.50.

Structure Therapeutics Price Performance

Structure Therapeutics stock traded down $1.77 during mid-day trading on Friday, reaching $62.98. The stock had a trading volume of 713,661 shares, compared to its average volume of 890,509. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The company has a 50-day moving average price of $75.41 and a two-hundred day moving average price of $46.54. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of -79.72 and a beta of -2.06.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, equities research analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CWM LLC increased its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. State of Wyoming purchased a new stake in shares of Structure Therapeutics in the second quarter worth $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $127,000. Finally, Assetmark Inc. raised its position in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.